Yesterday, we commented on top 10 medical innovations reported at the Cleveland Clinic Innovation Summit.
At the summit, Boston Scientific CEO Jim Tobin’s presentation underscored the other point we made recently, that acquisition is a routine part of medtech’s drive for innovation. Boston Scientific has some $2 billion on hand and is looking for companies whose products can contribute to top line growth, underscoring that startups with a more future potential are less of interest. The operative consideration is that revenues in the near term are important for Boston Scientific, as it recuperates from its expensive acquisition of Guidant. Tobin’s presentation was well described here.